AR and prostate carcinoma: Furthermore, KIF15 was reported to directly bind to the N-terminus of androgen receptor (AR)/AR-V7 and prevent the degradation of AR/AR-V7 proteins, which contributed to enzalutamide resistance in prostate cancer [20].